⚔️ NVO vs PDD vs EEFT vs CROX

📋 Executive Summary

Seven legendary investors — Buffett, Munger, Kantesaria, Tepper, Vinall, Pabrai, and Prasad — debated which of four deeply discounted businesses to own for the next decade: Novo Nordisk (NVO), PDD Holdings (PDD), Euronet Worldwide (EEFT), and Crocs (CROX). All four trade below 10× earnings, spanning pharmaceuticals, Chinese e-commerce, global payments, and footwear. The central tension: every stock looks cheap, but each carries a fundamentally different type of risk — competitive erosion, geopolitical governance, financial engineering fragility, or fashion cyclicality. Which bargain is real, and which is a trap?

• 🏆 Winner: Novo Nordisk (NVO) — 4 votes. Biological switching costs lock in 46 million chronic patients while the market prices this 43% ROIC franchise at just 10× earnings — despite fewer than 2% of the world's 890 million eligible obesity patients receiving treatment.

• 🥈 Runner-up: PDD Holdings (PDD) — 2 votes. Tepper and Vinall see reflexive China selling creating a once-in-a-cycle entry into a capital-light platform with $58 billion in cash cushioning the downside.

• ⚠️ Dividing risk: Whether Novo's moat protects the company or merely the drug class — Kantesaria's toll booth test revealed patients can switch to Lilly's tirzepatide without biological penalty, making this a duopoly rather than a monopoly.

• 💡 Surprising insight: Crocs at under 5× adjusted earnings yields 21% in free cash flow and retires 10% of shares annually, yet only Pabrai would accept fashion risk at that price — the council overwhelmingly preferred biological certainty over statistical cheapness.

• 🔢 Most decisive metric: The gap between NVO's implied growth rate of ~5.6% (what 10× earnings assumes) and the sub-2% global obesity penetration that supports double-digit growth for years — four of seven votes hinged on that mismatch.

The overarching lesson: when a franchise business earning 43% returns on capital trades at a single-digit earnings multiple, the margin of safety comes not from predicting the future perfectly, but from the sheer distance between what the market fears and what the biology guarantees.

PART 1: THE CONTENDERS

Buffett: "Let me lay out what we're choosing from today. Novo Nordisk sells weekly injections to chronic patients whose own biology punishes them for stopping treatment — gain back two-thirds of the weight within a year. PDD runs a digital bazaar where Chinese factories sell directly to 900 million consumers through team-purchase discounts that turn customers into unpaid salespeople. Euronet operates the plumbing of global payments — 54,000 ATMs, the world's third-largest remittance network, and digital content distribution across forty countries. And Crocs sells foam clogs at $55 a pair that cost $15 to make, with 61% gross margins and essentially no capital requirements. Here's the scorecard:"

"Every single one trades below 10× earnings. You rarely see four businesses this different all priced as though the world is ending. The question that matters most: which one of these is the market most wrong about?"

PART 2: BUSINESS QUALITY & MOATS

Munger: "Warren, I'll start by inverting — which of these four would I be most afraid to compete against if I had a billion dollars and five years? I could attack Crocs tomorrow. Hire a designer, get foam injection molding, slap a celebrity's name on it, and distribute through the same retailers. I might fail, but I'd have a real shot — Hoka and On Running proved that new comfort brands can break through in two or three years. I could attack Euronet too. Wise is already winning the highest-value remittance customers with structurally better digital unit economics. I could probably build a competing Chinese e-commerce platform with the right founder — Douyin is proving that right now, grabbing share from PDD in tier-one cities. But could I compete with Novo Nordisk in GLP-1 therapeutics? Not a chance. A decade of clinical trials, billions in R&D, regulatory approvals across a hundred countries, and manufacturing infrastructure that takes years to build. That competitive buffer isn't a brand or a network effect — it's inscribed in biology and regulation, and those are the two hardest barriers to replicate."

Kantesaria: "Charlie, I respect the inversion, but you're conflating class-level barriers with company-level moats, and that distinction changes everything. Nobody can easily enter GLP-1 therapy from scratch — you're right about that. But Eli Lilly already has entered, and they're winning. Novo grew U.S. GLP-1 revenue just 5% in 2025 while the overall market grew over 10%, which means they surrendered real share to Lilly's tirzepatide every single quarter. A patient on Ozempic can switch to Mounjaro without any biological penalty — the doctor writes a new script, the pharmacy fills it, and treatment continues uninterrupted. Compare that to the businesses I own: you cannot issue a bond in global capital markets without a Moody's or S&P rating, and even offering that rating for free cannot displace them because bonds without their stamp trade at a 30-50 basis point penalty. That's a mandatory checkpoint. Novo is one lane of a two-lane toll bridge, and the other lane is getting wider every quarter."

Tepper: "Dev, you're applying a framework designed for financial infrastructure and then acting surprised when a pharmaceutical company doesn't fit it perfectly. The real question isn't whether Novo is a monopoly — it's whether the market is right to price this duopoly at 10×. The combined GLP-1 market is $80 billion today and heading toward $150 billion by 2030 as international launches accelerate. Even if Novo's share settles at 45% instead of 55%, they earn more in absolute dollars on a much larger pie. History shows us that when two dominant players share a growing market — think about credit cards, think about aircraft engines — both companies earn extraordinary returns because neither has an incentive to destroy pricing. I see no credible third entrant with clinical data that threatens this dynamic."

Pabrai: "David, I hear you on Novo, but let me shift to a genuinely different kind of competitive advantage being ignored at this table. Crocs has cultural embeddedness at a scale that's hard to dismiss — 1.5 billion pairs sold over twenty years, a Jibbitz personalization ecosystem that parents tell me their kids collect like trading cards, and a manufacturing model that's fully outsourced with zero capital requirements. But here's my real question: at under 5× earnings, does the moat need to be permanent? If the brand sustains relevance for even five more years at these cash flow levels, the returns are extraordinary regardless. When the price is low enough, durability matters less than cash generation."

Prasad: "Mohnish, it absolutely matters, and Crocs' own history proves why. Between 2012 and 2014, ROIC collapsed from 23% to 2% in a single year because teenagers decided foam clogs weren't cool anymore. That's not an organism adapted for survival — that's a species dependent on favorable weather. Fashion is the fastest-changing competitive environment in consumer business, and I've spent my career avoiding exactly these dynamics. My test is whether an industry changes slowly enough that competitive advantages compound over decades. Human obesity is a permanent biological condition — the demand for Novo's product is encoded in metabolism, not in trend cycles. No cultural shift will make weight regain fashionable."

Vinall: "Pulak, the biological permanence argument for Novo is strong, but I want to push back because this group is underweighting PDD's competitive structure. The team-purchase model weaponized social networks for commerce in a way nobody has replicated — customers recruit other customers because the discount structure rewards group buying. That viral loop created a $54 billion revenue business at an asset intensity that's almost hard to believe. My real concern isn't PDD's moat — it's whether the Chinese regulatory environment respects private capital enough to let minority shareholders benefit. I own Chinese businesses through Prosus and H World, so I accept that risk framework. The question is whether PDD's VIE governance structure deserves the same trust."

Buffett: "Robert raises the question that keeps me away from PDD entirely. I've spent sixty years learning that the quality of a business matters less than the quality of the ownership structure when you're a minority shareholder. PDD is a variable interest entity — American shareholders own a claim on a Cayman Islands shell company with contractual rights to a Chinese operating business, but zero legal ownership of the actual assets. If Beijing decides those contracts are unenforceable, shareholders have no recourse and no court to appeal to. That's a risk I cannot quantify, and when I can't quantify a risk, I don't take it — full stop."

Munger: "Warren, I invested in Alibaba after a 70% drawdown using exactly that logic — that VIE risk was overpriced relative to business quality. I was wrong. The lesson wasn't that China is uninvestable; it was that the timing of regulatory intervention is unknowable. I'd rather own Novo at 10× with risks I can model — Lilly's market share gains, margin pressure from manufacturing ramp — than PDD at 10× with a risk I fundamentally cannot model. Quantifiable risks allow rational responses. Unquantifiable ones leave you paralyzed at exactly the wrong moment."

PART 3: FINANCIALS & TRACK RECORD

Kantesaria: "Charlie, since you've brought us to modelable risks, let me walk through Novo's financial character, because it's what forced me to reconsider my categorical pharma exclusion. Revenue compounded at 10.4% annually over thirteen years from $13.8 billion to $49.6 billion, but the trajectory that matters is the obesity franchise — from DKK 6 billion in 2019 to DKK 82 billion in 2025. That's a 14× increase in six years, and it now represents 27% of total revenue growing at 31% annually. When I see 43% ROIC maintained for fourteen consecutive years alongside that kind of franchise expansion, it looks less like pharma — where patent cliffs reset the clock — and more like a subscription infrastructure business where biology enforces the renewal. Starting from $3.67 EPS and growing at the 12% historical rate, ten years delivers roughly $11.40. Apply an 18× exit multiple — appropriate for a duopoly with decade-long runway — and you reach about $205, or 5.6× from today's $36.53. That's 18.8% annualized. Even if I haircut growth to 8% and the exit multiple to 15×, EPS reaches $7.92 and fair value is $119 — still a 3.3× return and 12.6% annualized. The margin between what's priced in and what's probable is enormous."

Vinall: "Dev, those Novo numbers are compelling, but let me run PDD through the same framework because the growth quality comparison is instructive. PDD went from $500 million in revenue in 2016 to $57 billion today — a hundredfold increase in eight years. Management explicitly warned against linear projection, and I take that seriously. But even at the 12% historical rate, $9.83 EPS compounds to $30.53 in a decade. Apply a more conservative 12× exit — reflecting China discount and governance uncertainty — and you get $366, or 3.8× from $96.19 today, roughly 14.3% annualized. The second-order effect that excites me: if PDD merely stabilizes domestically at 8% growth while Temu contributes nothing, the domestic platform alone justifies the entire market cap. Every dollar Temu earns is upside the market has priced at zero. That's a fundamentally different risk structure than paying 18× for Novo's continued execution."

Tepper: "Robert, that's the asymmetry I see, but let me add the reflexive dimension. PDD has dropped 60% from its peak, and the selloff has created its own gravity — passive funds rebalanced out, momentum traders shorted it, and the 'China uninvestable' narrative keeps institutional allocators away. Li Lu, Duan Yongping, and Norbert Lou are accumulating at these levels precisely because sentiment has detached from the underlying business. When PDD reported Q3 2025 with 9% revenue growth, the market treated it like a death sentence. But operating margins held at 22.4%, ROIC stayed at 24.2%, and the balance sheet carried virtually no net debt. The question nobody's answering is: where does that $58 billion in cash actually go? If management initiates meaningful buybacks at under 10× earnings, the per-share math compounds rapidly. If they burn it on Temu subsidies, returns compress. That capital allocation decision is the real swing variable — not the growth rate."

Pabrai: "David, PDD's math simply doesn't work for me — at $145 billion market cap, I'd need it to reach $435 billion for my required 3:1 payoff, larger than Alibaba ever achieved. The math does work at Crocs. Starting from $16 in adjusted EPS at the 12% historical rate, a decade gives me roughly $50 in EPS. Now, Pulak correctly noted that management guides 2-5% consolidated revenue growth, so let me stress-test with 8% growth instead — that gives $34.50 EPS. At a conservative 10× exit for a fashion business, that's $345 from $75.78, a 4.6× return or 16.4% annualized. But the buyback amplifier is what makes this work even if I'm wrong on growth. Management retired 10% of shares last year alone at prices below 5× earnings — that's the most accretive capital return program I've seen since auto dealerships in 2020. Even if the Crocs brand merely stagnates on revenue, per-share earnings compound at double digits through share retirement mechanics alone."

Prasad: "Mohnish, your 12% growth assumption deserves scrutiny because the source of that historical rate won't repeat. Crocs' explosive CAGR came from a turnaround that took ROIC from 2% to 27% — that's a one-time re-rating, not a sustainable trajectory. The Crocs brand grew revenue just 2% in 2025, North America declined 7%, and HEYDUDE is declining 14% annually after absorbing a $500 million impairment. Management paid $2.05 billion for HEYDUDE in 2022, and that acquisition has already destroyed roughly a quarter of its purchase price. Using your 8% scenario is more honest, and even that may prove optimistic if HEYDUDE continues consuming capital that should flow to buybacks."

Buffett: "Pulak makes a crucial point about growth quality that applies equally to Novo. The bulls cite 12% historical growth without examining where it originated — two-thirds of Novo's acceleration came from the obesity franchise, which barely existed before 2020. Revenue growth decelerated from 25% in 2023 to 10% in 2025, which is the natural maturing of a product cycle. But here's the second-order dynamic: the DKK 180 billion manufacturing buildout over 2023-2025 creates powerful operating leverage as CapEx normalizes. Those factories will produce at scale while the spending to build them fades from the income statement. Free cash flow should inflect sharply upward from the current DKK 40 billion level, and that inflection — not revenue acceleration — is what drives the next phase of per-share compounding."

Munger: "Warren, you've identified Novo's key financial catalyst, so let me bring Euronet into this comparison because it illustrates a fundamentally different financial character — and a cautionary one. Michael Brown has retired 15.4% of shares over seven years, which amplified FCF per share growth to 17% annually versus 10% revenue growth. That gap sounds wonderful until you look underneath. Operating cash flow collapsed 37% year-over-year while accounts receivable ballooned to $2.24 billion — more than half of trailing revenue. And here's the number that should concern everyone: Euronet cycled $8 billion in gross debt issuance and repayment in 2024 on a $3 billion market cap. That daily borrowing-and-repaying settlement machine works beautifully until a timing mismatch occurs on a Friday afternoon. At 10.1% ROIC — down from 16% in 2018 — the incremental capital being deployed is earning progressively less. That's a seven-year deterioration trend that the buyback program obscures rather than fixes."

PART 4: VALUATION & RETURN COMPARISON

Vinall: "Let me consolidate the projections we've walked through, because the comparison reveals something the individual analyses don't:"

"That implied growth row deserves the most attention. Working backward from each stock's P/E — assuming a 15× terminal multiple and a 10% required return — we can calculate what growth rate the market is embedding in today's price. The market prices Novo for roughly 5.6% growth, about half its historical rate. PDD and Euronet are similarly discounted. But Crocs stands out: the market is pricing in negative 2% growth, essentially betting the brand is in terminal decline. The gap between implied and probable is where investment returns live."

Tepper: "Robert, the implied growth analysis frames exactly why PDD is my preference. The market embeds 5.4% growth for a platform that delivered 59% last year and 9% in its worst recent quarter. Even in a scenario where Temu shuts down entirely and domestic growth settles at 8-10%, that's nearly double what's priced in. But I want to challenge your Novo exit multiple — 18× is generous for a pharmaceutical company losing relative market share. If Lilly's tirzepatide franchise captures the #1 position and Novo becomes the #2 player in a category it created, the market re-rates this to 12-14× regardless of earnings growth. At 14× and $11.40 EPS, you're at $160 — a 4.4× return, still excellent but materially below your table."

Kantesaria: "David, let me address the implied expectations for Novo directly, because this is where the mispricing becomes almost mathematical. At 10× earnings, the market believes Novo — with sub-2% global obesity penetration, 134% international Wegovy growth, and manufacturing capacity built for 10× the current patient base — will grow slower than nominal GDP for the next decade. That's not pricing in competition from Lilly. That's pricing in the business dying. Think one step further about the second-order consequences: if Novo delivers even 8% growth, its expanding installed base of manufacturing capacity generates operating leverage that accelerates free cash flow growth beyond revenue growth. The CapEx-heavy investment phase suppresses current FCF, which suppresses the multiple, which creates exactly the entry point that makes ten-year returns extraordinary. The market is confusing a temporary investment cycle with permanent impairment."

Pabrai: "Dev, the Novo math is appealing, but let me frame Crocs' risk-reward for the skeptics. My downside case: the brand enters another 2012-style decline, margins compress to 15%, and the stock trades at 8× reduced earnings of roughly $8 — about $64, a 15% loss from here. My upside case: China continues expanding, international reaches 60% of brand mix, HEYDUDE stabilizes, and EPS hits $25 in three years at 12× — that's $300, a 4× return. Heads I make 4×, tails I lose 15%. Nobody else in this table offers that asymmetry."

Buffett: "Mohnish, your downside case assumes a rational floor at $64, but fashion brands don't find rational floors during sentiment collapses. When Crocs entered its death spiral in 2013, it didn't settle at 8× trough earnings — it traded at 0.5× book value because the market couldn't determine what the business would earn two years out. That unpredictability is the risk the 4.7× multiple is compensating you for. With Novo, I know every one of those 46 million chronic patients will refill their prescription next month regardless of what's happening in fashion or culture. Predictability isn't a luxury at this table — it's the margin of safety itself."

PART 5: RISKS & SCENARIOS

Prasad: "Let me project forward to 2030 with a scenario nobody at this table wants to confront. Oral GLP-1 pills have become the standard of care — not injectables. Lilly launched an oral tirzepatide in 2028 that achieved 90% of injectable efficacy with dramatically better patient compliance. Novo's massive injectable manufacturing infrastructure — built at enormous cost over three years — becomes partially stranded assets. The ROIC drops not because demand disappeared, but because the capital base was optimized for the wrong delivery mechanism. This is the classic evolutionary trap: the best-adapted incumbent gets disrupted not by a new species, but by an environmental shift that turns its greatest strength into a liability. Novo is developing their own oral semaglutide, but the question is whether they can transition a manufacturing base designed for injectables quickly enough."

Vinall: "Pulak, that's a genuine risk for Novo. Let me raise one for PDD that's more immediate and harder to hedge. It's 2028 and the U.S. has eliminated the de minimis exemption entirely — every sub-$800 package from Temu now faces import duties that wipe out the price advantage that built the platform. Simultaneously, Douyin's commerce platform surpasses PDD domestically in tier-one and tier-two cities, confining Pinduoduo to lower-tier markets with structurally thinner margins. The cash pile — which David rightly flagged as the swing variable — has been deployed into merchant subsidies that generated growth on paper but destroyed per-unit returns. ROIC falls to 14%, and the compounding thesis is dead even though the business survives. That's the distinction investors miss: survival and compounding are very different outcomes."

Pabrai: "Let me address the CROX elephant directly — am I buying a rerun of 2013? Honestly, I might be. But the structural setup is different. In 2013, North America was 60% of revenue with zero geographic diversification. Today, international is 49% and China is growing at 30% off a tiny 8% base. The real thesis killer isn't fashion cyclicality — it's management stubbornness on HEYDUDE. They paid $2.05 billion for a brand now declining 14% annually, absorbed a $500 million impairment, and still insist they have 'conviction' in the strategy. Every dollar burned stabilizing a drowning brand is a dollar not returned through buybacks at under 5× earnings. If management announced a HEYDUDE divestiture tomorrow, the stock would probably jump 20% on capital allocation improvement alone."

Munger: "Let me flag a risk for Euronet that explains why nobody at this table is picking it despite superficially attractive numbers. The EU is systematically tightening regulation on dynamic currency conversion — that 5-8% FX spread tourists pay at Euronet ATMs without fully understanding the markup. Brussels already forced transparency disclosures, and the regulatory direction is unambiguous: spreads will compress. The ATM segment generates Euronet's highest margins, and those margins exist partly because consumers don't realize they're paying a premium. When regulation forces full disclosure, both volumes and margins compress simultaneously. It's the worst kind of regulatory risk — the kind that slowly erodes your best business over years rather than killing it cleanly. Combined with the settlement liquidity architecture we discussed and the declining ROIC trend, Euronet has too many structural headwinds to justify a position when the other three offer cleaner risk profiles."

PART 6: INVESTOR PICKS

🦅 Buffett's Pick — Novo Nordisk A/S (NVO): "Among these four, Novo Nordisk is the only business where I can sketch the earnings a decade from now in ink rather than pencil. The 370 basis points of gross margin compression that the bears fixate on reflects manufacturing depreciation flowing through during the biggest capacity buildout in company history — it's a transitory cost, not competitive pricing pressure. As the CapEx cycle I described earlier normalizes and factory utilization rises, free cash flow should inflect sharply upward from current levels, creating a compounding dynamic the current 10× multiple completely ignores. I'd rather own a duopoly with biologically enforced demand at a good price than a statistically cheaper business where I'm guessing whether cultural relevance survives the decade."

🦉 Munger's Pick — Novo Nordisk A/S (NVO): "Warren and I independently reached the same conclusion here, which itself is informative — that alignment happens perhaps once or twice a decade. Inverting the thesis, what permanently kills Novo? Not Lilly — duopolies with expanding markets are enormously profitable for both players, and neither has an incentive to destroy pricing when the untreated population exceeds 98%. Not the oral pill transition Pulak described — Novo is developing oral semaglutide alongside injectables, and a $50 billion company with 42% operating margins has the resources to manage a format transition. The only genuine killer would be a cure for obesity, which no credible researcher is predicting this decade. At 10× earnings, I'm being paid for patience with risks I can model. That's the right combination."

🎯 Kantesaria's Pick — Novo Nordisk A/S (NVO): "I'm breaking my categorical rule on pharma, and I want to be transparent about why. My framework avoids healthcare because outcomes typically aren't predictable over 5-10 years — patent cliffs, trial failures, and regulatory shifts make the cash flows too uncertain. But Novo's switching cost isn't a patent; it's physiology. Patients who discontinue therapy regain two-thirds of lost weight within twelve months, creating the closest thing to a metabolic toll bridge I've encountered in any industry. At a roughly 10% FCF yield versus a 4.3% risk-free rate, my back-of-envelope calculation points to obvious mispricing. The fourteen-year ROIC track record above 42% doesn't look like pharma economics — it looks like infrastructure economics wearing a lab coat."

🦁 Tepper's Pick — PDD Holdings Inc (PDD): "Among these four, PDD offers the most violent potential repricing if sentiment shifts — and sentiment toward China always shifts eventually. The stock is down 60% from its peak, passive funds have rebalanced out, and the smartest China-focused value investors on the planet are accumulating while Western consensus runs the other way. I'm buying the setup, not the story. At under 10× earnings with cash equal to 40% of market cap, the downside is limited to scenarios where Beijing actively destroys a major employer and tax contributor — possible, but improbable. The implied growth of 5.4% on a business that delivered 59% growth a year ago is the kind of sentiment-to-fundamentals mismatch I've built my entire career exploiting."

📚 Vinall's Pick — PDD Holdings Inc (PDD): "I own Chinese businesses through Prosus and H World because 'China is uninvestable' is historically the best signal to invest in China. PDD's team-purchase model created genuinely differentiated commerce mechanics — customers recruit customers, manufacturing sells direct — and the capital efficiency at 0.24% capex intensity is extraordinary among platforms at this revenue scale. My 15% hurdle rate is comfortable in the base case where domestic growth sustains at 8-10% and Temu contributes modestly, and the bear case — where Temu contributes zero — still delivers mid-single-digit returns cushioned by the enormous cash position. The governance risk Warren raised is real, but at under 10× earnings with that much cash on the balance sheet, I'm being compensated generously for bearing it."

🔥 Pabrai's Pick — Crocs Inc (CROX): "Among these four, Crocs is the only one where the math works for my framework. NVO and PDD both exceed $100 billion in market cap — I'd need them to triple for my required 3:1 payoff, and tripling a $145 billion or $172 billion business is asking for something history rarely delivers. Euronet's settlement liquidity architecture — cycling $8 billion annually on a $3 billion market cap — represents exactly the kind of hidden financial engineering risk I won't accept. At $75.78 and $4.5 billion market cap, I need Crocs at roughly $227 for my 3:1 target, which requires a mid-teens multiple on modestly growing earnings — achievable without heroic assumptions. The 21% free cash flow yield and 10% annual share retirement provide a compounding floor even if the brand merely holds steady. Yes, fashion is fickle. But at under 5× earnings, the price compensates for that fickleness better than anything else on this table."

🌿 Prasad's Pick — Novo Nordisk A/S (NVO): "Among these four, Novo Nordisk passes my evolutionary survival test more convincingly than any pharmaceutical company I've analyzed. The demand for this product is encoded in human biology — obesity is a chronic, progressive condition, and the global patient population grows every year as developing economies adopt calorie-dense diets. This is a permanently slow-changing competitive environment: the underlying biology doesn't evolve on human timescales, treatment adherence is physiologically enforced rather than contractually, and the duopoly structure with Lilly creates stable competitive equilibrium rather than destructive price wars. The manufacturing buildout phase that's suppressing current returns is the kind of temporary stress that well-adapted organisms absorb and emerge stronger from. At 10× earnings, I'm buying survival fitness at a distressed price."

PART 7: THE VERDICT

Vote Count:

• NVO: 4 votes (Buffett, Munger, Kantesaria, Prasad)

• PDD: 2 votes (Tepper, Vinall)

• CROX: 1 vote (Pabrai)

• Total: 7 votes

🏆 Winner: Novo Nordisk A/S (NVO) — 4 votes

🥈 Runner-up: PDD Holdings Inc (PDD) — 2 votes

⚠️ Dissent: Tepper and Vinall argued that PDD's reflexive selling and enormous cash position create a superior risk-adjusted entry, while Pabrai maintained that only Crocs' sub-$5B market cap and 21% FCF yield satisfy his asymmetric return requirements.

💡 Key Insight: The council overwhelmingly chose biological certainty over statistical cheapness — Crocs was the cheapest stock at 4.7× but attracted only one vote, while Novo at 10× attracted four, proving that predictability of cash flows matters more than absolute valuation level.

🎯 Takeaway: When a franchise business earning 43% returns on capital trades at 10× earnings because the market confuses a temporary investment cycle with permanent impairment, the distance between what's priced in (~5.6% growth) and what's probable (8-12% growth) creates a decade-long compounding opportunity that requires no heroic assumptions to capture.

Buffett: "The lesson here extends beyond these four stocks. The best investments aren't the ones that require you to be right about the future — they're the ones where the future has already been decided by forces that don't change. Biology doesn't negotiate. Eight hundred and ninety million people have a chronic condition, fewer than 2% are treated, and no amount of market sentiment changes that arithmetic. When you find that combination of certainty and price, the only real risk is overthinking it."